Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

View the 50 largest pharmaceutical companies in the world listings here

CSL Behring

CSL, including CSL Behring

Rank: 26

Melbourne (CSL Behring HQ in King of Prussia, Pa.), Australia
www.cslbehring.com

2020 Revenues ($USD) : $8,796,600,000
2020 R&D spend : $141,800,000
2020 Number of Employees : 27,000
Fiscal Year End : 6/30/2020
Key People : Paul Perreault, CEO

CSL Behring is a biotechnology company developing recombinant and plasma-derived technology for rare and serious diseases such as hemophilia, von Willebrand disease, primary immune deficiencies, chronic inflammatory demyelinating polyneuropathy, hereditary angioedema and inherited respiratory disease. Australia-based CSL's two product portfolios, CSL Behring and Seqirus, provide therapeutics and influenza vaccines to different global populations. –DK

CSL Behring

CSL Behring plans to expand its operations at its current site in Pasadena, Calif.

Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE